美媒：中国如何成为生物技术产业关键后勤基地

Core Insights - The article highlights China's emergence as a critical logistics hub for the biotechnology industry, shifting the focus from traditional sectors like semiconductors and manufacturing to life sciences and biotechnology [1][2] - Major Chinese cities such as Shanghai, Suzhou, Beijing, Shenzhen, and Guangzhou are developing dense life science industry clusters, with Shanghai's Zhangjiang Science City housing over 1,700 biopharmaceutical innovation entities [1] - China is becoming increasingly integrated into the global biotechnology supply chain, with many U.S. companies relying on Asian countries like China, India, and Singapore for efficient drug development processes [1] Industry Developments - China's clinical research ecosystem is rapidly maturing, with nearly one-third of global clinical trials expected to be conducted in China by 2024 [2] - The country offers multiple advantages in research, including lower operational costs, a large patient recruitment pool, and robust data infrastructure [2] - A prominent venture capital CEO has indicated that China is on a steady path to surpassing the U.S. in biotechnology leadership [2]